Exploring the Fecal Microbiome Dysbiosis and Its Plasma Metabolome Determinants in Advanced Parkinson's Disease With Motor Complications
CNS Neuroscience & Therapeutics · 2026
DOI: 10.1002/cns.70750 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2026. Verfasst von Shuangjie Qian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Parkinson Disease, Dysbiosis, Feces, Metabolome. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Projects of the National Science Foundation of China, the Projects of the Natural Science Foundation of Zhejiang Province, Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang.
Abstract (Originalsprache)
Background
Parkinson's disease with motor complications (PD‐MC) lacks effective diagnostic and therapeutic strategies. The perturbations of the gut microbiota and plasma metabolites are closely associated with the etiopathogenesis of PD. However, whether fecal microbiome dysbiosis and changed plasma metabolites are involved in PD progression, particularly in the development of PD‐MC, is still unclear.
Methods
In this study, we performed an extensive multiomics analysis involving 108 PD patients for 16S rRNA gut microbiome profiling and 246 PD patients for plasma nontargeted metabolomics. Our findings revealed distinct gut microbiota and plasma metabolites associated with PD‐MC. Utilizing these discriminative features, we developed a multivariate diagnostic model for PD‐MC. The relationships between differential metabolites and microorganisms were evaluated using Spearman correlation analysis. Functional interpretation of the key metabolites was conducted through enrichment and pathway analysis, employing the KEGG and SMPDB databases.
Results
PD‐MC patients had distinct gut microbial signatures as compared with PD without motor complications (PD‐NMC) individuals and were increased in fecal Lactobacillus, Limosilactobacillus, Bifidobacterium, and Ligilactobacillus genera along with depleted Agathobacter. Moreover, metabolomic analysis revealed the differences in plasma 3‐deoxysappanchalcone (3‐DSC), 1,3‐Dimethyluracil (1,3‐DTl), Leucine, and N‐Acetylisoleucine (N‐AIL), Dodec‐6‐enoic acid (D‐6‐E), N‐butyl Oleate (N‐BO), and 4‐hydroxyundecanoic acid (4‐HUA) in PD‐MC compared to PD‐NMC. Spearman correlation analysis showed that the fecal microbiota aberrations in PD‐MC patients were linked to plasma metabolic changes, indicating the association between key microbial populations and metabolomic profiles in PD‐MC.
Conclusions
This study underscores the value of employing integrated multiomics profiling of the fecal microbiome and plasma metabolome to enhance the mechanistic understanding of PD‐MC and to identify potential diagnostic biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Oujiang Laboratory, Wenzhou, Zhejiang, China.
- Department of Geriatrics, Geriatric Medical Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
ORCID-Profile: Hongchang Gao, Chenglong Xie
Förderung
- Projects of the National Science Foundation of China
- the Projects of the Natural Science Foundation of Zhejiang Province
- Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang
- the "Pioneer" and "Leading Goose" R&D Program of Zhejiang Province
- The Projects of the Wenzhou City Committee of Science and Technology
Zitieren
APA
Qian, S., Hou, J., Xiong, X., Duan, Q., Jiang, T., Zheng, Y., Quan, W., Xu, J., Chen, K., Qian, J., Gao, H., & Xie, C. (2026). Exploring the Fecal Microbiome Dysbiosis and Its Plasma Metabolome Determinants in Advanced Parkinson's Disease With Motor Complications. CNS Neuroscience & Therapeutics. https://doi.org/10.1002/cns.70750
Vancouver
Qian S, Hou J, Xiong X, Duan Q, Jiang T, Zheng Y, et al. Exploring the Fecal Microbiome Dysbiosis and Its Plasma Metabolome Determinants in Advanced Parkinson's Disease With Motor Complications. CNS Neuroscience & Therapeutics. 2026. doi:10.1002/cns.70750
BibTeX
@article{Qian2026,
author = {Qian, Shuangjie and Hou, Jialong and Xiong, Xi and Duan, Qi and Jiang, Tao and Zheng, Yi and Quan, Weiwei and Xu, Jiaxue and Chen, Keke and Qian, Jingjing and Gao, Hongchang and Xie, Chenglong},
title = {Exploring the Fecal Microbiome Dysbiosis and Its Plasma Metabolome Determinants in Advanced Parkinson's Disease With Motor Complications},
journal = {CNS Neuroscience & Therapeutics},
year = {2026},
doi = {10.1002/cns.70750}
}
EUVIMED